Higher Relapse Rate With Rituximab vs Ocrelizumab in MS Registry Data

(MedPage Today) -- Rituximab (Rituxan) did not show noninferiority compared with ocrelizumab (Ocrevus) in relapsing-remitting multiple sclerosis (MS), according to registry data.
The annualized relapse rate (ARR) was higher in MS patients treated...